Amy Baremore
Psychiatric/Mental Health · Joplin, MONPI 1578193637
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 407 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Supernus Pharmaceuticals, Inc.$994
- Otsuka America Pharmaceutical, Inc.$894
- Neurocrine Biosciences, Inc.$816
- Axsome Therapeutics, Inc.$613
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$517
- plus $3K from 19 others
What the payments were for
- Food & beverage$8,27799%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 107 | $1,856 |
| Supernus Pharmaceuticals, Inc. | 68 | $994 |
| Otsuka America Pharmaceutical, Inc. | 57 | $894 |
| Neurocrine Biosciences, Inc. | 29 | $816 |
| Axsome Therapeutics, Inc. | 16 | $613 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $517 |
| Alkermes, Inc. | 11 | $407 |
| Johnson & Johnson | 14 | $406 |
| Teva Pharmaceuticals USA, Inc. | 9 | $363 |
| E.r. Squibb & Sons, L.L.C. | 4 | $284 |
| Vanda Pharmaceuticals Inc. | 13 | $263 |
| Lundbeck LLC | 12 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $197 |
| Corium, LLC | 18 | $157 |
| Jazz Pharmaceuticals Inc. | 6 | $100 |
| Indivior Inc. | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Eisai Inc. | 3 | $42 |
| Pfizer | 2 | $28 |
| Novo Nordisk | 1 | $19 |
| Orexo US, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$982
- INGREZZA$259
- CAPLYTA$228
- INVEGA SUSTENNA$152
- QELBREE$127
- Auvelity$125
- UZEDY$125
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- Fanapt$123
- Austedo XR$123
- VRAYLAR$123
- REXULTI$123
- COBENFY$122
How this compares
$8,366 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $195,538 |
| CaplytaLumateperone Tosylate | 25 | $34,736 |
| VraylarCariprazine Hcl | 12 | $19,679 |
| TrintellixVortioxetine Hydrobromide | 32 | $15,492 |
| Lamotrigine | 60 | $721 |
| Trazodone Hcl | 53 | $678 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $596 |
| Duloxetine Hcl | 25 | $541 |
| Clonazepam | 30 | $464 |
| Benztropine Mesylate | 23 | $432 |
| Gabapentin | 29 | $406 |
| Mirtazapine | 49 | $339 |
| Oxcarbazepine | 25 | $318 |
| Bupropion XlBupropion Hcl | 14 | $244 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $816 | $195,53823 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $517 | $34,73625 claims |
| AbbVieVraylar | $1,856 | $19,67912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $197 | $15,49232 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $5712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Joplin
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
- Kelsey KingsboroughMexico$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.